Nanomedicine promises to deliver exciting new therapeutic approaches for a range of conditions of huge concern to society, including macular degeneration and cancer. This project will develop the fundamental understanding required for novel light-responsive nanomaterials as new improved treatment options for these diseases, by enabling 'on-demand' release of drug at the site of action. Ultimately, treatment for patients will be less invasive with fewer side effects, and social and commercial value will result through better health outcomes, and provide a new mechanism for growth in the Australian biotechnology industry.
|Effective start/end date||1/12/12 → 31/12/16|
- Australian Research Council (ARC): AUD622,856.00
- Australian Research Council (ARC): AUD175,671.00